Sarepta Therapeutics

Youtube Subscribe

Open: 122.0 Close: 121.27 Change: -0.73

The 9 top things that an AI found about Sarepta Therapeutics Stock and you do not know…

Are looking for the most relevant information about Sarepta Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Sarepta Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sarepta Therapeutics are: Sarepta, Therapeutics, rating, treat, SRPT, Inc, stock, and the most common words in the summary are: sarepta, therapeutic, stock, duchenne, srpt, analyst, news, . One of the sentences in the summary was: Success would also provide validation to the PPMO platform and could …

Concept Map

Semantic Network

Stock Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing SRP-.

Today's Summary

Sarepta Therapeutics gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial. Success would also provide validation to the PPMO platform and could see expansion into patients beyond just the exon 51 skipping population. Average price target for Sareptpt Therapeuticss is $138.

Today's News

Sarepta Therapeutics stock price, quote & news - stock analysis. Success would also provide validation to the PPMO platform and could see expansion into patients beyond just the exon 51 skipping population. William Blair sees SRP-5051 replacing Exondys 51. Sarepta Therapeutics gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell Monday. Sarepta Therapeutics (SRPT) Company Description: Sareptas Therapeutic earns ‘buy rating on promising dmd drug study results | markets insider. Buy rating on sarepta therapeutics. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. Analyst Ratings convey expectations for the relative performance of Sareptpt Therapeuticss. Sarepta Therapeutics, Inc. (SRPT) NASDAQ: SRPT · IEX Real-Time Price · USD Add to Watchlist 121.27 -1.56 (-1.27%) At close: Feb 2, 2024, 4:00 PM 119.83 -1:44 (-1:19%) After-hours: Feb. 2, 24 hours of analysis gives you a free - BGM Classic€ civic 1899 Globcludes Plenty instantaneous Korea angles recol Sarepta Therapeutics has begun screening patients for EMERGENE, a phase 3 clinical trial (NCT identifier pending) that will evaluate SRP-9003 (bidridistrogene xeboparvovec), an investigational adeno-associated virus (AAV) vector-based gene therapy intended to treat limb-girdle muscular dystrophy Type 2E (LGMD2E/WMPF ) Tak citiesirt Gri ENTER Dund Sarepta Therapeutics Inc. has a conensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings. The average price target for Sareptpt Therapeuticss is $138.86.

Stock Profile

"Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Sarepta Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sarepta Therapeutics are: Sarepta, Therapeutics, rating, treat, SRPT, Inc, stock, and the most common words in the summary are: sarepta, therapeutic, stock, duchenne, srpt, analyst, news, . One of the sentences in the summary was: Success would also provide validation to the PPMO platform and could see expansion into patients beyond just the exon 51 skipping population. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sarepta #therapeutic #stock #duchenne #srpt #analyst #news.

Read more →

Youtube Subscribe

---